Efficiency of adalimumab, etanercept and infliximab in rheumatoid arthritis patients: dosing patterns and effectiveness in daily clinical practice.

Abstract

OBJECTIVES This retrospective, multicentre, observational study aimed to assess the mean annual doses and associated costs of three anti-tumour necrosis factor agents in daily clinical practice in rheumatoid arthritis patients, correlating these costs with disease activity. METHODS Adult rheumatoid arthritis patients were treated and followed at the… (More)

Topics

Cite this paper

@article{RamrezHerriz2013EfficiencyOA, title={Efficiency of adalimumab, etanercept and infliximab in rheumatoid arthritis patients: dosing patterns and effectiveness in daily clinical practice.}, author={Esther Ram{\'i}rez-Herr{\'a}iz and Vicente Escudero-Vilaplana and Estefan{\'i}a Ala{\~n}{\'o}n-Plaza and Nicol{\'a}s Trovato-L{\'o}pez and Ana Herranz-Alonso and Alberto Morell-Baladr{\'o}n and Mar{\'i}a Sanjurjo-S{\'a}ez}, journal={Clinical and experimental rheumatology}, year={2013}, volume={31 4}, pages={559-65} }